芪卫通痹口服液治疗稳定期久痹类风湿关节炎患者的有效性和安全性。

Efficacy and Safety of Qiwei Tongbi Oral Liquid in Patients with Stable Long-Standing Rheumatoid Arthritis.

机构信息

Department of Rheumatology and Immunology, The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, China.

Traditional Chinese Medicine Department, The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, China.

出版信息

Biomed Res Int. 2021 Oct 23;2021:3930800. doi: 10.1155/2021/3930800. eCollection 2021.

OBJECTIVE

Our study is aimed at investigating the efficacy and safety of Qiwei Tongbi oral liquid in patients with stable long-standing rheumatoid arthritis (RA).

METHOD

140 patients with stable long-standing RA were recruited into the Qiwei Tongbi oral liquid group or the control group. At study recruitment and after 12 weeks of treatment, their C-reactive protein (CRP) levels, interleukin-6 (IL-6) levels, erythrocyte sedimentation rate (ESR), Health Assessment Questionnaire (HAQ), visual analogue scale (VAS), and Disease Activity Score (DAS) 28 were compared in two groups.

RESULTS

Patients in the Qiwei Tongbi oral liquid group had a lower level of CRP, IL-6, VAS scale, and HAQ score compared to patients in the control group (CRP: 3.51 ± 1.57 vs.5.47 ± 1.72 mg/L, < 0.001; IL-6: 1.62 ± 0.8 vs. 2.19 ± 0.88 pg/mL, < 0.001; VAS scale: 1.59 ± 0.69 vs. 2.66 ± 1.02, < 0.001; and HAQ score: 1.19 ± 0.46 vs. 1.41 ± 0.50, = 0.005). The ESR and DAS28 did not reach statistical difference. No damage to liver and kidney functions was observed in both groups.

CONCLUSION

Qiwei Tongbi oral liquid has the tendency to decrease the inflammation levels and pain score and improve patients' outcomes in patients with stable long-standing RA.

目的

本研究旨在探讨芪卫通痹口服液治疗稳定期长病程类风湿关节炎（RA）的疗效和安全性。

方法

将 140 例稳定期长病程 RA 患者纳入芪卫通痹口服液组或对照组。在研究入组时和治疗 12 周后，比较两组患者的 C 反应蛋白（CRP）、白细胞介素-6（IL-6）、红细胞沉降率（ESR）、健康评估问卷（HAQ）、视觉模拟评分（VAS）和疾病活动评分（DAS）28。

结果

与对照组相比，芪卫通痹口服液组患者的 CRP、IL-6、VAS 评分和 HAQ 评分均较低（CRP：3.51 ± 1.57 比 5.47 ± 1.72 mg/L， < 0.001；IL-6：1.62 ± 0.8 比 2.19 ± 0.88 pg/mL， < 0.001；VAS 评分：1.59 ± 0.69 比 2.66 ± 1.02， < 0.001；和 HAQ 评分：1.19 ± 0.46 比 1.41 ± 0.50， = 0.005）。ESR 和 DAS28 未达到统计学差异。两组均未观察到肝肾功能损害。